ES2967259T3 - Detección y tratamiento de la deficiencia de la hormona del crecimiento - Google Patents

Detección y tratamiento de la deficiencia de la hormona del crecimiento Download PDF

Info

Publication number
ES2967259T3
ES2967259T3 ES21192867T ES21192867T ES2967259T3 ES 2967259 T3 ES2967259 T3 ES 2967259T3 ES 21192867 T ES21192867 T ES 21192867T ES 21192867 T ES21192867 T ES 21192867T ES 2967259 T3 ES2967259 T3 ES 2967259T3
Authority
ES
Spain
Prior art keywords
test
child
use according
growth
ghd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21192867T
Other languages
English (en)
Spanish (es)
Inventor
Michael Thorner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lumos Pharma Inc
Original Assignee
Lumos Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumos Pharma Inc filed Critical Lumos Pharma Inc
Application granted granted Critical
Publication of ES2967259T3 publication Critical patent/ES2967259T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ES21192867T 2015-09-21 2016-09-21 Detección y tratamiento de la deficiencia de la hormona del crecimiento Active ES2967259T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562221191P 2015-09-21 2015-09-21
US201662289221P 2016-01-30 2016-01-30

Publications (1)

Publication Number Publication Date
ES2967259T3 true ES2967259T3 (es) 2024-04-29

Family

ID=58276481

Family Applications (2)

Application Number Title Priority Date Filing Date
ES21192867T Active ES2967259T3 (es) 2015-09-21 2016-09-21 Detección y tratamiento de la deficiencia de la hormona del crecimiento
ES16849470T Active ES2908423T3 (es) 2015-09-21 2016-09-21 Detección y tratamiento de la deficiencia de la hormona del crecimiento

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16849470T Active ES2908423T3 (es) 2015-09-21 2016-09-21 Detección y tratamiento de la deficiencia de la hormona del crecimiento

Country Status (23)

Country Link
US (5) US9763919B2 (enExample)
EP (3) EP3352752B1 (enExample)
JP (5) JP6816149B2 (enExample)
KR (4) KR20230116961A (enExample)
CN (2) CN108348501A (enExample)
AU (5) AU2016328969B2 (enExample)
CA (1) CA2998523C (enExample)
CY (1) CY1125183T1 (enExample)
DK (2) DK3939590T3 (enExample)
ES (2) ES2967259T3 (enExample)
FI (1) FI3939590T3 (enExample)
HR (1) HRP20220317T1 (enExample)
HU (2) HUE065224T2 (enExample)
IL (1) IL258224B (enExample)
LT (1) LT3352752T (enExample)
PL (2) PL3939590T3 (enExample)
PT (2) PT3939590T (enExample)
RS (1) RS62988B1 (enExample)
SG (2) SG10202010598SA (enExample)
SI (1) SI3352752T1 (enExample)
SM (1) SMT202200167T1 (enExample)
UA (1) UA123865C2 (enExample)
WO (1) WO2017053373A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
CN108348501A (zh) * 2015-09-21 2018-07-31 埃莫奈特药业有限责任公司 检测和治疗生长激素缺乏症
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
EP3840854A4 (en) 2018-08-20 2022-06-29 Bessor Pharma, LLC Novel cannabinoids and cannabinoid acids and their derivatives
US11644474B2 (en) * 2020-07-22 2023-05-09 Æterna Zentaris Gmbh Use of macimorelin in assessing growth hormone deficiency in children
GEAP202516774A (en) 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650597A4 (en) * 1992-06-29 1996-12-18 Univ South Florida DIAGNOSTIC METHOD FOR EVALUATING THE AETIOLOGY OF MINOR GROWTH.
US5756507A (en) 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU758160B2 (en) * 1997-08-22 2003-03-20 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
ATE302181T1 (de) * 2000-06-13 2005-09-15 Zentaris Gmbh Verbindungen zur stimulation der sekretion von wachstumshormonen
US20070037861A1 (en) * 2003-09-19 2007-02-15 Pfizer Health Ab Enhanced method of treatment of growth disorders
AU2004288831B2 (en) * 2003-11-12 2010-08-26 Phenomix Corporation Heterocyclic boronic acid compounds
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
US20150119327A1 (en) * 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
US11234969B2 (en) * 2016-01-30 2022-02-01 Lumos Pharma, Inc. Detecting and treating growth hormone deficiency
CN108348501A (zh) * 2015-09-21 2018-07-31 埃莫奈特药业有限责任公司 检测和治疗生长激素缺乏症

Also Published As

Publication number Publication date
PT3352752T (pt) 2022-03-09
UA123865C2 (uk) 2021-06-16
US20170079961A1 (en) 2017-03-23
SG10202010598SA (en) 2020-11-27
AU2016328969B2 (en) 2020-10-08
US12539293B2 (en) 2026-02-03
CN108348501A (zh) 2018-07-31
JP2024026112A (ja) 2024-02-28
PL3939590T3 (pl) 2024-03-25
EP3939590B1 (en) 2023-11-29
ES2908423T3 (es) 2022-04-29
PL3352752T3 (pl) 2022-04-19
HUE057831T2 (hu) 2022-06-28
HRP20220317T1 (hr) 2022-05-13
FI3939590T3 (fi) 2023-12-14
KR20250102122A (ko) 2025-07-04
AU2020233715B2 (en) 2021-09-30
CY1125183T1 (el) 2023-06-09
SG10201902424TA (en) 2019-04-29
JP7104768B2 (ja) 2022-07-21
HK1263178A1 (zh) 2020-01-31
AU2024201658C1 (en) 2026-02-12
AU2025237934A1 (en) 2025-10-16
AU2024201658A1 (en) 2024-04-04
JP7389862B2 (ja) 2023-11-30
US20220142989A1 (en) 2022-05-12
US10105352B2 (en) 2018-10-23
US10898472B2 (en) 2021-01-26
DK3939590T3 (da) 2023-12-18
AU2016328969A1 (en) 2018-04-26
KR20180082428A (ko) 2018-07-18
EP3352752A1 (en) 2018-08-01
IL258224A (en) 2018-05-31
JP2018529766A (ja) 2018-10-11
SMT202200167T1 (it) 2022-05-12
IL258224B (en) 2021-10-31
KR102385669B1 (ko) 2022-04-13
CA2998523C (en) 2023-08-01
NZ741142A (en) 2025-05-02
HUE065224T2 (hu) 2024-05-28
RS62988B1 (sr) 2022-03-31
JP2021063096A (ja) 2021-04-22
EP4296679A2 (en) 2023-12-27
US20190015394A1 (en) 2019-01-17
US20180071266A1 (en) 2018-03-15
CA2998523A1 (en) 2017-03-30
JP7724831B2 (ja) 2025-08-18
KR20220047407A (ko) 2022-04-15
AU2020233715A1 (en) 2020-10-22
AU2021254600A1 (en) 2021-11-18
US9763919B2 (en) 2017-09-19
KR20230116961A (ko) 2023-08-04
LT3352752T (lt) 2022-04-11
WO2017053373A1 (en) 2017-03-30
CN116459250A (zh) 2023-07-21
EP3939590A1 (en) 2022-01-19
AU2024201658B2 (en) 2025-10-30
JP2022163012A (ja) 2022-10-25
EP3352752B1 (en) 2021-12-22
AU2021254600B2 (en) 2024-02-15
KR102560838B1 (ko) 2023-07-27
SI3352752T1 (sl) 2022-05-31
JP2025170274A (ja) 2025-11-18
PT3939590T (pt) 2024-01-23
JP6816149B2 (ja) 2021-01-20
EP3352752A4 (en) 2019-06-12
US20250213536A1 (en) 2025-07-03
DK3352752T3 (da) 2022-02-28
EP4296679A3 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
ES2908423T3 (es) Detección y tratamiento de la deficiencia de la hormona del crecimiento
US11234969B2 (en) Detecting and treating growth hormone deficiency
HK40068057B (en) Detecting and treating growth hormone deficiency
HK40105706A (en) Detecting and treating growth hormone deficiency
HK40068057A (en) Detecting and treating growth hormone deficiency
HK40096494A (en) Detecting and treating growth hormone deficiency
HK1263178B (en) Detecting and treating growth hormone deficiency